Novartis announced the closure of Shan Dushi Pharmaceutical Factory, real gold and silver all in innovative medicine?

Novartis announced the closure of Shan Dushi Pharmaceutical Factory, real gold and silver all in innovative medicine?

Source: Same freehand

Following the layoffs of 1,400 people in Switzerland, Novartis announced that a few days ago, it would close the Sands Photos Pharmaceutical Factory in Wilson, North Carolina.

The factory has about 246 employees who are engaged in the sales of oral solid -stricken preparation products in the United States and Canada. The factory is expected to be completely closed around 2023.

In late August, Novartis announced that it plans to peel off its pharmaceutical department Yam Dex and listed it as an independent company in Switzerland. Novartis will focus on innovative drugs.

According to reports, Sanders' business is mainly the production of biotechnology and non -prescription drugs. Last year, sales reached 9.6 billion US dollars, accounting for nearly one -fifth of Nova's total sales, and carried out business in more than 100 markets around the world. However, due to the continuous decline in Yamadz ’s revenue for many years and the pressure of generic drugs, as early as October last year, Novartis announced that it would conduct audit on how to handle the various options of Samstez.

In addition to reorganizing the "God of Labor" for its own organizational structure, the research data of several best -selling drugs in Novartis are also quite "hard work".

On August 12, a report stated that two patients receiving Nuohua spinal muscle atrophy (SMA) gene therapy died of acute liver failure. Zolgensma gene therapy seems effective, but the known potential side effects are to cause liver problems.

On August 15th, Novartis announced its anti-cancer drug Canakinumab III stage Canopy-A test results, which aims to test Canakinuma's role in adult non-small cell lung cancer (NSCLC). Unfortunately, the test failed to reach the main end point: Disease -free survival (DFS).

However, it is not all bad news.

Novartis recently disclosed the positive results of cosentyx in Phase III in patients with purulent sweat glamulitis (HS) patients, which indicates that Cosentyx is expected to become a new choice for HS patients who need to be treated urgently.

HS is a skin disease, which is characterized by the recurrent mass (nodule) rupture under the skin and cause abscess.

The Sunny project, including Sunshine and Sunrise, is the largest III phase of HS. The test recruited more than 1,000 patients in 33 countries/regions, and the effect of two doses of Cosentyx was evaluated within 16 weeks and 52 weeks.

Novartis said that in the 16 weeks of the two tests, after conducting standard doses of standards, when receiving cosentyx 300mg every 2 weeks, higher percentage patients showing a clinical response to purulent sweaturitis (HISCR, HISCR, HISCR, Defining as abscess and inflammatory nodules is at least 50%lower than the baseline, and the abscess and drainage fistula count did not increase).

In the SUNRISE test, after the standard dosage of the standard, the use of the same dose every 4 weeks also proves that HISCR is better than the placebo group in it, but this data has no statistically significant significance in SUNSHINE.

The specific data will be announced at the 31st EADV conference. Novartis has also submitted these data to European regulators and hopes to submit data to the FDA before the end of the year.

Cosentyx is the first and only one that directly suppress human white aggrite-IL-17A antagonist, and has previously approved 5 adaptive diseases. Human Baijiexin 17A is an important cytokine, involving psoriasis arthritis (PSA), moderate to severe plaques psoriasis, ankylosing spondylitis (AS), and non -radioxidal axes (NR NR -AXSPA).

In addition, Kisqali and monoclonal antibody Tislelizumab of Nuohua breast cancer drugs also achieved positive results in the test.

Kisqali and endocrine therapy added a year's overall survival in the first-line treatment of the sub-group of HR+/HER2-advanced breast cancer patients; TisleLizumab was a test of patients with patients with previously treated and irregular hepatocytium carcinoma (HCC). Successful. It is worth mentioning that Tislelizumab's III phase test is conducted in cooperation with Baiji Shenzhou. The test compared Tislelizumab with Sorafenib. The data will be announced on ESMO.

In terms of independent production capacity, Novartis will also focus on the concept of "innovative products".

Or, thanks to the total shares held to Roche (53.3 million free circulation shares, which accounts for about 33%of Roche's total number of free circulation shares) to Roche last year at Roche for $ 20.7 billion). Various investment.

On September 12, Novartis announced that it would invest 300 million US dollars on the next generation of biological therapy, including the development of drugs and drug products, involving factories in Switzerland, Slovenia and Austria. Novartis will also invest 100 million US dollars in the Nuohua Saint John Park in Basel, Switzerland, to supplement the existing NIBR biological agent center.

In Slovenia's Megus, Novartis will invest $ 110 million for non -CGMP and CGMP clinical manufacturing capacity, and plans to invest 60 million US dollars to improve its development and manufacturing capabilities in the Austrian Schaftenau park.

In addition to selling other stocks held by them, Novartis also announced a $ 15 billion stock repurchase plan, but Novartis plans to retain enough cash and invest in other companies and technologies when necessary.Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform.If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -